<div id="readability-page-1"><p>AlphaQuest LLC lifted its holdings in  Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 26.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor  owned 13,338 shares of the company's stock after purchasing an additional 2,818 shares during the quarter. AlphaQuest LLC's holdings in Johnson &amp; Johnson were worth $2,212,000 as of its most recent SEC filing.</p><ul><li>JNJ Stock Surge Signals Confidence in New Growth Path</li></ul><p>Other institutional investors and hedge funds have also bought and sold shares of the company. Highline Wealth Partners LLC grew its stake in  Johnson &amp; Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares in the last quarter.  Stone House Investment Management LLC acquired a new position in  Johnson &amp; Johnson during the first quarter worth $47,000.  von Borstel &amp; Associates Inc. acquired a new position in  Johnson &amp; Johnson during the first quarter worth $49,000.  Capital A Wealth Management LLC acquired a new position in  Johnson &amp; Johnson during the fourth quarter worth $50,000.  Finally, Harvest Fund Management Co. Ltd acquired a new position in  Johnson &amp; Johnson during the first quarter worth $52,000. Institutional investors own  69.55% of the company's stock. </p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities analysts recently weighed in on the stock. Morgan Stanley boosted their target price on shares of Johnson &amp; Johnson from $171.00 to $176.00 and gave the stock an &#34;equal weight&#34; rating in a report on Thursday, July 17th. Benchmark upgraded shares of Johnson &amp; Johnson to a &#34;strong-buy&#34; rating in a report on Thursday, April 24th. Piper Sandler  reiterated an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a report on Thursday, July 17th. Citigroup upped their price objective on shares of Johnson &amp; Johnson from $185.00 to $200.00 and gave the company a &#34;buy&#34; rating in a report on Thursday. Finally, Barclays upped their price target on shares of Johnson &amp; Johnson from $165.00 to $176.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued  a Hold rating to the company. According to data from MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $176.29.</p><ul><li>3 Big Dividend Plays With Strong Earnings to Back Them</li></ul><p><b>Check Out Our Latest Report on JNJ</b></p><h2>Johnson &amp; Johnson Trading Up 0.0%</h2><p>JNJ stock opened at $178.8990 on Friday. Johnson &amp; Johnson has a 52 week low of $140.68 and a 52 week high of $180.61. The company's 50-day simple moving average is $163.04 and its 200 day simple moving average is $159.05. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market capitalization of $430.85 billion, a PE ratio of 19.13, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41. </p><ul><li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson &amp; Johnson's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.82 earnings per share.  Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts anticipate that  Johnson &amp; Johnson will post 10.58 earnings per share for the current year. </p><h2>Johnson &amp; Johnson Dividend Announcement</h2><p>The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson &amp; Johnson's dividend payout ratio  is 55.61%. </p><h2>Johnson &amp; Johnson Company Profile</h2> (Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>See Also</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>How to Effectively Use the MarketBeat Ratings Screener</li><li>Small Cap, Big Potential: 3 Tech Disruptors You Should Know About</li><li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li><li>After Earnings Miss, Walmart Is Still a Top Consumer Staples Play</li><li>Best Energy Stocks - Energy Stocks to Buy Now</li><li>How Cisco Is Building a New Growth Story for Investors</li></ul><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>AlphaQuest LLC increased its stake in Johnson & Johnson (NYSE: JNJ) by 26.8% in Q1, acquiring an additional 2,818 shares, bringing its total to 13,338 shares valued at $2.21 million. Other institutional investors also raised their holdings. Analysts have a consensus rating of "Moderate Buy" for JNJ, with a target price averaging $176.29. The company reported Q2 earnings of $2.77 per share, exceeding estimates, and announced a quarterly dividend of $1.30, payable on September 9.</p>

AlphaQuest LLC Acquires 2,818 Shares of Johnson & Johnson $JNJ